Differential pharmacology and benefit/risk of azilsartan compared to other sartans
Vascular Health and Risk Management, 2012 Theodore W Kurtz1, Takashi Kajiya21Department of Laboratory Medicine, University of California, San Francisco, CA, USA ; 2Department of Cardiovascular, Respiratory, and Metabolic Medicine, Graduate School of Medicine, Kagoshima University, Kagoshima ...
Kurtz TW, Kajiya T
doaj
What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment? [PDF]
, 2012 Hypertension has a major associated risk for organ damage and mortality, which is further heightened in patients with prior cardiovascular (CV) events, comorbid diabetes mellitus, microalbuminuria and renal impairment.
Mallat, Samir G
core +3 more sources
FORMULATION AND EVALUATION OF POLYMERIC NANOSUSPENSION OF NARINGENIN [PDF]
, 2017 Objective: The objective of this study was to formulate and evaluate the poorly soluble drug, naringenin (NAR) into nanosuspension to increase the solubility and enhance the dissolution rate and then improve its bioavailability.Methods: Nanosuspenion of ...
Sivakumar, T. +2 more
core +3 more sources
Using Different Analytical Techniques and Synthetically Tailored Silica Nanoparticles in Drug Separations and Hydrophobicity-Based Detection Applications [PDF]
, 2017 The development and validation of accurate and reliable analytical methods using techniques such as capillary electrophoresis, liquid chromatography, UV-spectrophotometry, spectrofluorimetry and mass spectrometry for separation and determination of some ...
Abdelwahab, Walid
core +2 more sources
Kardiologiia, 2017 To study effects of a fixed azilsartan medoxomil/chlorthalidone combination (Edarbi Clo) on clinical, ambulatory and central blood pressure (BP) in patients with uncontrolled arterial hypertension (AH)).Patients (n=25) with uncontrolled AH were given fixed azilsartan medoxomil/chlorthalidone combination (40 / 12.5 mg / day) for 4 weeks.
Kobalava Z.D. +2 more
openaire +5 more sources
Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation [PDF]
, 2014 Since the introduction of the German health care reform in January 2011, an early benefit assessment (EBA) is required for all new medicines. Pharmaceutical manufacturers have to submit a benefit dossier for evaluation by the Institute for Quality and ...
Dintsios, Charalabos-Markos +3 more
core +2 more sources
Azilsartan reduced TNF-α and IL-1β levels, increased IL-10 levels and upregulated VEGF, FGF, KGF, and TGF-α in an oral mucositis model [PDF]
, 2015 Oral mucositis (OM) is a common complication of treatments for head and neck cancer, particularly radiotherapy with or without chemotherapy. OM is characterised by oral erythema, ulceration, and pain.
Araújo Júnior, Raimundo Fernandes de +6 more
core
PROTECTION AND TOLERABILITY OF AZILSARTAN MEDOXOMIL IN RESPONDENTS WITH IMPORTANT HYPERTENSION
, 2020 The current 58-week, level 4, open-label, two-partner, successive, non-randomized study assessed well-being and poor quality of inessential hypertension due to azelastine minoxidil (AZL-M) (baseline mean blood pressure 152/100 mmHg). Altogether focuses (n¼669) began taking 42 mg QD of AZL-M, the potency was increased to 80 mg QD at week 5, whenever ...
openaire +1 more source
SOLUBILITY AND DISSOLUTION ENHANCEMENT OF PIOGLITAZONE USING SOLID DISPERSION TECHNIQUE [PDF]
, 2017 Objective: To design the study to improve the solubility and hence enhance the dissolution of hydrophobic drug Pioglitazone in order to increase its bioavailability.Methods: Solid dispersion of Pioglitazone using carriers Poloxomer 188 and HPβCD was ...
Bhairav, Bhushan A. +2 more
core +1 more source
How does Angiotensin II Receptor Blocker (ARB) Therapy Compare to Angiotensin Converting Enzyme (ACE) Inhibitor Therapy in Prevention of Long-Term Complications in Idiopathic Hypertension? [PDF]
, 2019 Medical evidence to date confirms that ACE inhibitors and ARBs provide equivalent blood pressure control. However, for prevention of specific outcomes, the data show stronger support for ACE inhibitors than ARBs, and vice-versa.
Saxe, Makenzie
core +1 more source